Recursion Pharmaceuticals prices $200 million underwritten stock offering
+1 new source since this summary was written
Recursion Pharmaceuticals announced that it has priced an underwritten public offering of 61,540,000 Class A common shares at $3.25 each. The company expects to collect roughly $200 million in gross proceeds before underwriting discounts, commissions and other estimated costs. The sale is slated to close around October 16, 2026, pending standard closing conditions. The offering is being managed by a syndicate that includes Leerink Partners, Goldman Sachs, Morgan Stanley and Evercore, with Needham & Company as lead manager.
Why it matters
The proceeds will provide additional capital for Recursion’s AI‑driven drug discovery programs and ongoing R&D efforts, according to the company’s press release. The timing of the closing means the funds could be available before the start of the next fiscal quarter, potentially supporting upcoming clinical milestones.
Key facts
- 1Recursion priced an underwritten offering of 61,540,000 Class A common shares at $3.25 per share. stocktitan.net
- 2The company anticipates gross proceeds of about $200 million before underwriting discounts, commissions and other estimated expenses. stocktitan.net
- 3The offering is expected to close around October 16, 2026, subject to customary closing conditions. thewhig.com
- 4Joint book‑running managers are Leerink Partners, Goldman Sachs & Co., Morgan Stanley & Co. and Evercore Group. stocktitan.net
- 5Needham & Company serves as lead manager for the offering. stocktitan.net
- 6The shares are being sold pursuant to a Form S‑3 registration statement that became effective on February 12, 2025. stocktitan.net
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.